purchase customization

1 Study Coverage
1.1 Multiple Sclerosis (MS) Drugs Product Introduction
1.2 Global Multiple Sclerosis (MS) Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Multiple Sclerosis (MS) Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Multiple Sclerosis (MS) Drugs Sales in Volume for the Year 2017-2028
1.3 United States Multiple Sclerosis (MS) Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Multiple Sclerosis (MS) Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Multiple Sclerosis (MS) Drugs Sales in Volume for the Year 2017-2028
1.4 Multiple Sclerosis (MS) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Multiple Sclerosis (MS) Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Multiple Sclerosis (MS) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Multiple Sclerosis (MS) Drugs Market Dynamics
1.5.1 Multiple Sclerosis (MS) Drugs Industry Trends
1.5.2 Multiple Sclerosis (MS) Drugs Market Drivers
1.5.3 Multiple Sclerosis (MS) Drugs Market Challenges
1.5.4 Multiple Sclerosis (MS) Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Multiple Sclerosis (MS) Drugs Market Segment by Type
2.1.1 Copaxone (Glatiramer Acetate, Copolymer 1)
2.1.2 Novantrone (Mitoxantrone)
2.1.3 Gilenya (Fingolimod, Fty720)
2.1.4 Aubagio (Teriflunomide)
2.1.5 Tecfidera (Dimethyl Fumarate)
2.1.6 Firategrast (Sb683699, T-0047)
2.1.7 Siponimod (Baf312)
2.1.8 Others
2.2 Global Multiple Sclerosis (MS) Drugs Market Size by Type
2.2.1 Global Multiple Sclerosis (MS) Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Multiple Sclerosis (MS) Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Multiple Sclerosis (MS) Drugs Market Size by Type
2.3.1 United States Multiple Sclerosis (MS) Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Multiple Sclerosis (MS) Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Multiple Sclerosis (MS) Drugs Market Segment by Application
3.1.1 RRMS
3.1.2 SPMS
3.1.3 PPMS
3.1.4 PRMS
3.2 Global Multiple Sclerosis (MS) Drugs Market Size by Application
3.2.1 Global Multiple Sclerosis (MS) Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Multiple Sclerosis (MS) Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Multiple Sclerosis (MS) Drugs Market Size by Application
3.3.1 United States Multiple Sclerosis (MS) Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Multiple Sclerosis (MS) Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Multiple Sclerosis (MS) Drugs Competitor Landscape by Company
4.1 Global Multiple Sclerosis (MS) Drugs Market Size by Company
4.1.1 Top Global Multiple Sclerosis (MS) Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Multiple Sclerosis (MS) Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Multiple Sclerosis (MS) Drugs Price by Manufacturer (2017-2022)
4.2 Global Multiple Sclerosis (MS) Drugs Concentration Ratio (CR)
4.2.1 Multiple Sclerosis (MS) Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Multiple Sclerosis (MS) Drugs in 2021
4.2.3 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Multiple Sclerosis (MS) Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Multiple Sclerosis (MS) Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Multiple Sclerosis (MS) Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Multiple Sclerosis (MS) Drugs Market Size by Company
4.5.1 Top Multiple Sclerosis (MS) Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Multiple Sclerosis (MS) Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Multiple Sclerosis (MS) Drugs Sales by Players (2020, 2021 & 2022)
5 Global Multiple Sclerosis (MS) Drugs Market Size by Region
5.1 Global Multiple Sclerosis (MS) Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Multiple Sclerosis (MS) Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Multiple Sclerosis (MS) Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Multiple Sclerosis (MS) Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Multiple Sclerosis (MS) Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Multiple Sclerosis (MS) Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Multiple Sclerosis (MS) Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Multiple Sclerosis (MS) Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Multiple Sclerosis (MS) Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Multiple Sclerosis (MS) Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Bayer AG
7.1.1 Bayer AG Corporation Information
7.1.2 Bayer AG Description and Business Overview
7.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Products Offered
7.1.5 Bayer AG Recent Development
7.2 Bayhill Therapeutics
7.2.1 Bayhill Therapeutics Corporation Information
7.2.2 Bayhill Therapeutics Description and Business Overview
7.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
7.2.5 Bayhill Therapeutics Recent Development
7.3 Biogen Idec
7.3.1 Biogen Idec Corporation Information
7.3.2 Biogen Idec Description and Business Overview
7.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Products Offered
7.3.5 Biogen Idec Recent Development
7.4 Cinnagen
7.4.1 Cinnagen Corporation Information
7.4.2 Cinnagen Description and Business Overview
7.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Products Offered
7.4.5 Cinnagen Recent Development
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Corporation Information
7.5.2 Daiichi Sankyo Description and Business Overview
7.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Products Offered
7.5.5 Daiichi Sankyo Recent Development
7.6 Eli Lilly
7.6.1 Eli Lilly Corporation Information
7.6.2 Eli Lilly Description and Business Overview
7.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Products Offered
7.6.5 Eli Lilly Recent Development
7.7 Fast Forward Llc
7.7.1 Fast Forward Llc Corporation Information
7.7.2 Fast Forward Llc Description and Business Overview
7.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Products Offered
7.7.5 Fast Forward Llc Recent Development
7.8 Antisense Therapeutics
7.8.1 Antisense Therapeutics Corporation Information
7.8.2 Antisense Therapeutics Description and Business Overview
7.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
7.8.5 Antisense Therapeutics Recent Development
7.9 Apitope
7.9.1 Apitope Corporation Information
7.9.2 Apitope Description and Business Overview
7.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Apitope Multiple Sclerosis (MS) Drugs Products Offered
7.9.5 Apitope Recent Development
7.10 Five Prime Therapeutics
7.10.1 Five Prime Therapeutics Corporation Information
7.10.2 Five Prime Therapeutics Description and Business Overview
7.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
7.10.5 Five Prime Therapeutics Recent Development
7.11 Genmab
7.11.1 Genmab Corporation Information
7.11.2 Genmab Description and Business Overview
7.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Genmab Multiple Sclerosis (MS) Drugs Products Offered
7.11.5 Genmab Recent Development
7.12 Artielle Immunotherapeutics
7.12.1 Artielle Immunotherapeutics Corporation Information
7.12.2 Artielle Immunotherapeutics Description and Business Overview
7.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Artielle Immunotherapeutics Products Offered
7.12.5 Artielle Immunotherapeutics Recent Development
7.13 Genzyme
7.13.1 Genzyme Corporation Information
7.13.2 Genzyme Description and Business Overview
7.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Genzyme Products Offered
7.13.5 Genzyme Recent Development
7.14 Glaxosmithkline
7.14.1 Glaxosmithkline Corporation Information
7.14.2 Glaxosmithkline Description and Business Overview
7.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Glaxosmithkline Products Offered
7.14.5 Glaxosmithkline Recent Development
7.15 Gw Pharmaceuticals
7.15.1 Gw Pharmaceuticals Corporation Information
7.15.2 Gw Pharmaceuticals Description and Business Overview
7.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Gw Pharmaceuticals Products Offered
7.15.5 Gw Pharmaceuticals Recent Development
7.16 Innate Immunotherapeutics
7.16.1 Innate Immunotherapeutics Corporation Information
7.16.2 Innate Immunotherapeutics Description and Business Overview
7.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Innate Immunotherapeutics Products Offered
7.16.5 Innate Immunotherapeutics Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Multiple Sclerosis (MS) Drugs Industry Chain Analysis
8.2 Multiple Sclerosis (MS) Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Multiple Sclerosis (MS) Drugs Distributors
8.3 Multiple Sclerosis (MS) Drugs Production Mode & Process
8.4 Multiple Sclerosis (MS) Drugs Sales and Marketing
8.4.1 Multiple Sclerosis (MS) Drugs Sales Channels
8.4.2 Multiple Sclerosis (MS) Drugs Distributors
8.5 Multiple Sclerosis (MS) Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer